Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

An Incitative Multifaceted PROcedure for Pneumococcal Vaccination at the Emergency Department (IMPROVED)

22. januar 2020 oppdatert av: Centre Hospitalier Princesse Grace

An Incitative Multifaceted PROcedure for Pneumococcal Vaccination at the Emergency Department; A Multicenter Prospective Randomized Open Trial The IMPROVED Project

Background :

Community-acquired pneumonia (CAP) is a threat in industrialized countries. It represents the 6th cause of death. CAP also frequently associates with other disorders responsible for admission and death. Among bacteria responsible for CAP, Streptococcus pneumonia is a major pathogen that is commonly involved and frequently leads to severe infection and admission. Categories at risk for this pathogen have been determined, and can be proposed anti-pneumococcal vaccination (APV) that efficiently and safely protects from this microorganism.

In the context of US health services, monocenter pilot experiences have reported improvement of pneumococcal prophylaxis implementing vaccination procedure at ED. A study that set in New Mexico (2003) reported a significant increase in APV (from 18% to 84%) when patients at risk were proposed vaccination at ED. To obtain these results, medical students were specifically trained and dedicated to screen and vaccinate against St. pneumoniae. Another single center trial (Tennessee, 2007) for APV at ED obtained an improvement (from 38.8 to 45.4%) when physicians were alerted for pneumococcal risk by the software they usually utilized at bedside. However these experiences remain sparse as additional dedicated resources are required or patients and attending ED physicians can be reluctant to proceed to vaccination at ED.

Mobile phone and derived communication modalities are current vectors to deliver information in several fields including education and medicine. Initially used in developing countries, short-message services (SMS) have improved behaviour of patients in various medical areas. In France, the investigators have observed that most patients above 50 years of age admitted after ED visit are equipped with mobile phone and can receive alerts by SMS.

These observations prompt us to propose a multifaceted procedure to improve APV after ED visit in at-risk patients, combining structured oral interview, written information and SMS as reminders.

Purpose : The investigators hypothesized that

  • a multifaceted intervention to promote anti-pneumococcal vaccination combining a structured oral interview, a written information to patient and his/her general practitioner, and a series of 3 SMS,
  • improves anti-pneumococcal vaccination at 6 months,
  • in at-risk patients (65+ years) visiting the emergency department. In order to answer this question, the investigators designed an interventional prospective multicenter randomized study (cluster).

Studieoversikt

Status

Fullført

Studietype

Observasjonsmessig

Registrering (Faktiske)

1475

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Clermont-ferrand, Frankrike, 63003
        • Centre Hospitalier Universitaire de Clermont-Ferrand
      • Issoire, Frankrike, 63503
        • Centre Hospitalier Paul Ardier
      • Marseille, Frankrike, 13015
        • AP-HM - Hôpital Nord
      • Marseille, Frankrike, 13385
        • AP-HM - La Timone
      • Marseille, Frankrike, 13915
        • Hia Laveran
      • Menton, Frankrike, 06507
        • Centre Hospitalier La Palmosa
      • Nice, Frankrike, 06003
        • Centre Hospitalier Universitaire De Nice
      • Orange, Frankrike, 84106
        • Centre Hospitalier Louis Giorgi
      • Paris, Frankrike, 75010
        • Hôpital Lariboisière
      • Paris, Frankrike, 75679
        • Hôpital Cochin
      • Paris, Frankrike, 75020
        • Hôpital Tenon
      • Paris, Frankrike, 75018
        • Hôpital Bichat-Claude Bernard
      • Paris, Frankrike, 75013
        • Hôpital Pitié-Salpêtrière
      • Saint-denis, Frankrike, 93200
        • Centre Hospitalier de Saint-Denis
      • Vaison-la-romaine, Frankrike, 84110
        • Centre Hospitalier de Vaison-la-Romaine
      • Valreas, Frankrike, 84600
        • Centre Hospitalier Jules Niel
      • Vichy, Frankrike, 03207
        • Centre Hospitalier Jacques Lacarin
      • Monaco, Monaco, 98000
        • Centre Hospitalier Princesse Grace

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

65 år og eldre (Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

patient aged 65 years or over who is not vaccinated against pneumoccocus virus during consultation with medical emergencies

Beskrivelse

Inclusion Criteria:

  • patients 65-year old and above,
  • benefit from French or Monaco social security a social security.

Exclusion Criteria:

  • refuse to participate,
  • no possibility to receive SMS,
  • impaired cognitive functions and mental status precluding understanding of the study,
  • anticipated barriers precluding adequate follow-up (ex. homeless),
  • previous APV,
  • contraindication to APV,
  • do not understand/read French.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Multifaceted
  • brief structured interview with the physician about pneumococcal risk and vaccination,
  • information sheet delivered to patients with explanation about risk and benefit of APV,
  • letter given to patient for his/her general practitioner stating that the patient is at-risk for pneumococcal infection and could benefit of APV,
  • 3 SMS every 2 weeks to remind patients talking of pneumococcal risk with general practitioner.
Control
  • information sheet delivered to patients with explanation about the aim of the study,
  • brief interview with the physician about study.

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Impact of a multifaceted procedure at ED visit on anti-pneumococcal vaccination. (APV) at 6-month. Evaluation criteria : Δ percentage (%) of APV vaccination at 6-month
Tidsramme: 6 month
6 month

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
On Flu vaccination at 6-month Δ percentage (%)
Tidsramme: 6 month
number of patients receiving vaccination against flu at 6-month. This issue will be collected by phone (patient, relative or general practioner). This will be a declarative data
6 month
On episodes of respiratory tract infections requiring antibiotics or admission at 6-month Δ (absolute number of events)
Tidsramme: 6 month
number of patients who experienced respiratiory tract infection requiring antibiotics or admission. This issue will be collected by phone at 6-month (patient, relative or general practioner). This will be a declarative data
6 month
On death at 6- and 12-month (absolute number of events)
Tidsramme: 6 month
6 month
On death related to infection at 6- and 12-month (absolute number of events)
Tidsramme: 6 month
6 month
Psychosocial evaluation of patients and acceptance / refusal of vaccination
Tidsramme: 6 month
The patient will fil a Psychosocial evaluation questionnaire during the ED visit. To achieve this issue, we will use the socio-economic indicators mobilized in investigations in social epidemiology: sex, age, education, occupation, housing, income and household size. This composite questionnaire will be used for qualitative analysis.
6 month

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Yann-Erick CLAESSENS, MD-PhD, Centre Hospitalier Princesse Grace
  • Studieleder: Xavier DUVAL, MD-PHD, Groupe Hospitalier Bichat Claude-Bernard
  • Studieleder: José LABARERE, MD, University Hospital, Grenoble
  • Studieleder: Jocelyn RAUDE, PHD, Ecole des Hautes Etudes en Santé Publique

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. november 2015

Primær fullføring (Faktiske)

1. oktober 2016

Studiet fullført (Faktiske)

1. oktober 2017

Datoer for studieregistrering

Først innsendt

4. juli 2013

Først innsendt som oppfylte QC-kriteriene

11. juli 2013

Først lagt ut (Anslag)

15. juli 2013

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

23. januar 2020

Siste oppdatering sendt inn som oppfylte QC-kriteriene

22. januar 2020

Sist bekreftet

1. oktober 2017

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere